Novartis Prexige NDA Has Data Vs. COX-2s; Forest Filing Lexapro Extensions
This article was originally published in Pharmaceutical Approvals Monthly
Novartis’ NDA for its COX-2 inhibitor Prexige, contains clinical studies in osteoarthritis, rheumatoid arthritis, acute pain (including postoperative and dental) and primary dysmenorrhea.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class